Tempus AI (NASDAQ:TEM) EVP Sells $383,541.21 in Stock

by · The Cerbat Gem

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) EVP Andrew Polovin sold 8,703 shares of the stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $383,541.21. Following the completion of the transaction, the executive vice president owned 128,215 shares of the company’s stock, valued at $5,650,435.05. The trade was a 6.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Andrew Polovin also recently made the following trade(s):

  • On Friday, February 20th, Andrew Polovin sold 10,949 shares of Tempus AI stock. The stock was sold at an average price of $60.31, for a total value of $660,334.19.

Tempus AI Trading Up 1.3%

Shares of NASDAQ:TEM traded up $0.61 during midday trading on Thursday, hitting $46.49. 3,802,434 shares of the stock were exchanged, compared to its average volume of 5,629,236. The stock has a market capitalization of $8.35 billion, a price-to-earnings ratio of -27.03 and a beta of 3.99. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31. The business’s 50-day moving average price is $49.11 and its 200 day moving average price is $59.69. Tempus AI, Inc. has a 12 month low of $41.73 and a 12 month high of $104.32.

Tempus AI (NASDAQ:TEM – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.08. The firm had revenue of $348.12 million during the quarter, compared to the consensus estimate of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The company’s revenue for the quarter was up 36.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.24) earnings per share. Analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Institutional Investors Weigh In On Tempus AI

Hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. boosted its stake in Tempus AI by 1,459.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock worth $8,174,000 after acquiring an additional 94,783 shares in the last quarter. Vanguard Group Inc. boosted its stake in Tempus AI by 22.1% during the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after acquiring an additional 1,706,837 shares in the last quarter. Hussman Strategic Advisors Inc. bought a new stake in Tempus AI in the 3rd quarter valued at about $1,695,000. Krane Funds Advisors LLC increased its position in Tempus AI by 218.2% in the 3rd quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock valued at $2,427,000 after buying an additional 19,358 shares in the last quarter. Finally, Aberdeen Group plc increased its position in Tempus AI by 64.2% in the 4th quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock valued at $15,530,000 after buying an additional 102,878 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on TEM shares. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price target on shares of Tempus AI in a research report on Wednesday, March 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. BTIG Research lowered their price target on shares of Tempus AI from $90.00 to $80.00 and set a “buy” rating for the company in a report on Friday, May 8th. Robert W. Baird began coverage on shares of Tempus AI in a report on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price target for the company. Finally, JPMorgan Chase & Co. decreased their price target on Tempus AI from $80.00 to $60.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Tempus AI has a consensus rating of “Moderate Buy” and an average target price of $68.64.

View Our Latest Stock Analysis on Tempus AI

Tempus AI Company Profile

(Get Free Report)

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

Featured Articles